Page results
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
This page is for parents and carers whose child is having radiotherapy treatment to the pelvis.
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
-
Short videos on managing cancer pain, cancer-related fatigue and improving sleep
-
At UCLH we run seasonal COVID-19 vaccination clinics from our Hospital Hub within UCH. Vaccinations are available to members of the eligible public as well as UCLH patients.
-
This page has been written for parents and carers whose child is having radiotherapy treatment to the spine (backbone).
-
This page has been written for parents and carers whose child is having total body irradiation (TBI) for leukaemia, lymphoma, or some other rare blood disorder.
-
This page has been written for parents and carers whose child is having radiotherapy treatment to the whole brain and spine. This treatment may also be referred to as whole central nervous system (CNS) or cranio-spinal radiotherapy.
-
Information covering a range of conditions. Search by condition name or condition type (specialty).
File results
-
FOI/2024/0462 - Patient information leaflets and e-consent systems
-
FOI/2024/0198 - Nurse intake at Band 5
-
FOI/2024/0199 - Admission and discharge policies for violent assault injuries/ autism/ patient records/ inaccurate records
-
FOI/2024/0204 - Clinical insourcing for audiology and pathology
-
FOI/2024/0206 - Trusts budget allocated for cancer funding 2019/20-2023/24
-
FOI/2024/0207 - Physician Associates and prescribing/ ionising radiation
-
FOI/2024/0214 - Treatment for myeloproliferative neoplasms
-
FOI/2024/0219 - Incidence and treatment of colorectal cancer
-
FOI/2024/0221 - Inbound patient enquiries
-
FOI/2024/0223 - Treatment of cancer secondary care